Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden.
Drug Discov Today. 2018 Jan;23(1):12-16. doi: 10.1016/j.drudis.2017.07.016. Epub 2017 Aug 3.
Since the importance of drug target residence time was first highlighted more 10 years ago, slow binding kinetics has received much attention in the drug discovery literature, and indeed within pharmaceutical research. However, the residence concept as presented in most papers is supported by rather misleading simulations and arguments, and by examples where compounds are taken out of their pharmacokinetic context. Moreover, fast association is typically more desirable than slow, and advantages of long residence time, notably a potential disconnect between pharmacodynamics (PD) and pharmacokinetics (PK), would be partially or completely offset by slow on-rate. Therefore, plain potency is likely a better predictor of drug development success than is residence time.
自 10 多年前首次强调药物靶点停留时间的重要性以来,缓慢的结合动力学在药物发现文献中,甚至在药物研究中受到了广泛关注。然而,大多数论文中提出的停留概念得到了相当误导性的模拟和论证的支持,也得到了将化合物从其药代动力学环境中取出的例子的支持。此外,快速结合通常比缓慢结合更可取,而长停留时间的优势,特别是药效学(PD)和药代动力学(PK)之间潜在的脱节,可能会被缓慢的结合速率部分或完全抵消。因此,与停留时间相比,单纯的效力可能是药物开发成功的更好预测指标。